Get the Stockscreener App
0.8503
6.49%
0.0518
Traws Pharma Inc stock is traded at $0.8503, with a volume of 857.16K.
It is up +6.49% in the last 24 hours and down -51.69% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
See More
Previous Close:
$0.7985
Open:
$0.7985
24h Volume:
857.16K
Relative Volume:
0.39
Market Cap:
$12.88M
Revenue:
$2.73M
Net Income/Loss:
$-19.43M
P/E Ratio:
-0.3739
EPS:
-2.2739
Net Cash Flow:
$-17.91M
1W Performance:
-33.05%
1M Performance:
-51.69%
6M Performance:
-31.98%
1Y Performance:
-48.47%
1-Day Range:
$0.7488
$0.8503
1-Week Range:
$0.64
$1.31
52-Week Range:
$0.64
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
0.8503 | 12.88M | 2.73M | -19.43M | -17.91M | -2.2739 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
TRAW Downgraded by HC Wainwright & Co. -- Price Target Adjusted to $1.00 - GuruFocus
Traws Pharma Inc (TRAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Why Did TRAW Stock Slump 28% After Hours? - Stocktwits
Traws Pharma Inc (TRAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Traws Pharma Inc (TRAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Traws Pharma Inc (TRAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Traws Pharma (TRAW) Plunges Over 32%: Support Test and Liquidity ConcernsSentiment Extreme - newsline.com
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
Traws Pharma stock falls as UK regulator delays key flu study - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma shares slide after UK regulator postpones influenza study - MSN
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com Australia
Micron, Nebius surge premarket; Traws Pharma tumbles - Investing.com
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma Provides Regulatory Update on Influenza Program - Sahm
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma Defers Phase 2a Influenza Study Plans - TipRanks
Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review - Quiver Quantitative
Traws Pharma Provides Regulatory Update on Influenza Program | Associated Press | syndication news - Enidnews.com
Regulator setback stalls Traws Pharma bird flu drug test in humans - Stock Titan
Traws Pharma (NASDAQ: TRAW) defers Phase 2a influenza study, advances backup antivirals with runway to Q1 2027 - Stock Titan
Traws Pharma (TRAW) Finds Support, Edges Higher With Modest GainContinuation Pattern Picks - newsline.com
Traws Pharma, Inc. (TRAW) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Traws Pharma (TRAW) Edges Lower as Stock Consolidates Near Key SupportBPI Bear Correction - newsline.com
Traws Pharma Q1 2026 Earnings: EPS Surprise Beats Estimates Despite No Revenue, Stock Declines 7.4%SaaS Earnings Trends - newsline.com
Traws Pharma Dips as Company Expands Outbreak Drug Play - Bez Kabli
Traws Pharma (TRAW) Holds Near Key Support Amid Modest UptickVolume Nodes - newsline.com
TRAW | Traws Pharma, Inc. Common Executive Compensation - Quiver Quantitative
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEstimate Accuracy - The Legal Advocate
Traws Pharma (NASDAQ: TRAW) 2026 proxy seeks share plan and warrant approvals - Stock Titan
Newtown-based Traws Pharma advances experimental antiviral therapy - Pennsylvania Business Report -
TRAW Q1 2026 Earnings: Narrower-than-Expected Loss Surprises on Lower ExpensesEarnings Recovery Stocks - The Legal Advocate
Traws Pharma announces new antiviral program - BioWorld News
Traws Pharma (TRAW) Hovers Just Above Support, Testing Resistance at $1.60Momentum Factor - newsline.com
TRAW Advances Novel Anti-Viral Agent for Hantavirus and Ebola - GuruFocus
Traws Pharma Advances Broad-Spectrum Antiviral for Emerging Outbreaks - TipRanks
Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) advances broad antiviral for Hantavirus, Ebola - Stock Titan
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks - GlobeNewswire
Traws Pharma, Inc. Files Form 8-K with SEC – Company Details, Address, and Legal Opinion Included - Minichart
TRAW - Finviz
Traws Pharma Updates ATM Equity Offering Prospectus Supplements - TipRanks
Traws Pharma launches $3.13M ATM sales under $50M shelf with Citizens JMP - TradingView
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):